ACTA’s Article 2.X on Injunctions: the July 1, 2010 text
From the July 1, 2010 text of ACTA:
Article 2.X InjunctionsACTA Provisions on Injunctions and Damages
KEI has issued a new research note, Comments on ACTA Provisions on Injunctions and Damages, KEI Research Note 2010:1, dated April 6, 2010.
IP Remedies: Injunctions
Among the available remedies for intellectual property right infringement are injunctions or monetary relief. Especially in copyright and patent infringement cases, injunctions have been considered as the usual and de facto automatic remedy to prevent, deter or stop infringement. Injunctions may however also impose high costs on society.
Notes on limitations to injunctions in the United States
The following are selected examples of U.S. law practices in the enforcement of intellectual property rights, with a particular emphasis on cases where there are limits on injunctive relief.
India limitations on injunctions
Copyright
In the Indian Copyright Act of 1957, there are limits on injunctive relief for cases involving architectural plans.
Canada limitations on injunctions
Copyright
Canada's copyright law contains limits to the ability for parties to obtain injunctive relief for architectural works:
ACTA and changes in global norms for damages and injunctions (for enforcement of intellectual property)
The Obama Administration, with the support of a Democrat-controlled U.S. Congress, is insisting the Anti-Counterfeiting Trade Agreement (ACTA) negotiations be conducted in secret. We know, from documents obtained in Europe and the summaries released in April 2009, that the draft ACTA has sections that deal with both injunctions and damages. We don’t have the current text. Continue Reading
Damages, Injunctions and Transparency key issues in ACTA negotiations
The decision to restart the ACTA negotiations makes it important to understand the nature and consequence of proposed agreement. Following a complaint about transparency, this note focuses on damages and injunctions.
Delhi High Court approves the sale of biosimilar nivolumab in the public interest
On Monday, 12 January 2026 a division bench of the Delhi High Court comprised of Justice Hari Shankar and Justice Om Prakash Shukla approved the sale of a biosmilar version of nivolumab, a cancer drug marketed by the firm Zydus… Continue Reading
Delhi High Court Rejects Roche’s Appeal, Paving Way for Affordable Generic Risdiplam
Below is a short note on good news on a court case in India concerning access to risdiplam, a treatment for spinal muscular atrophy (SMA). The note is followed by a statement on the case by Third World Network (TWN),… Continue Reading